People: Entera Bio Ltd (ENTX.OQ)

ENTX.OQ on NASDAQ Stock Exchange Capital Market

21 Feb 2020
Change (% chg)

$-0.31 (-9.25%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Toledano, Miranda 

Ms. Miranda Jayne Toledano serves as Independent Director of the Company. She is a partner at Fund7, a newly formed private equity firm and serves as Chief Financial Officer of TRIGR Therapeutics, a clinical stage immuno-oncology company focused on bispecific antibodies. Previously, Ms. Toledano served on the executive management team of Sorrento Therapeutics as EVP Corporate Development from September 2016 until August 2017. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed equity capital market transactions totaling over $4 billion in aggregate value. Prior to joining MLV, from 2004 until 2010, Ms. Toledano served in the investment group of Royalty Pharma, a leading investment firm with over $15 billion in biotherapeutic royalty assets. From 1998 to 2003, Ms. Toledano led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano holds a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --